Related Experiment Video
Updated: Mar 30, 2026

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
Published on: May 21, 2019
MicroRNA-7 Compromises p53 Protein-dependent Apoptosis by Controlling the Expression of the Chromatin Remodeling
Chun-Fu Hong1, Shu-Yu Lin2, Yu-Ting Chou3
1From the Department of Long Term Care, National Quemoy University, Kinmen County 89250.
Abstract:
We previously demonstrated that the epidermal growth factor receptor (EGFR) up-regulated miR-7 to promote tumor growth during lung cancer oncogenesis. Several lines of evidence have suggested that alterations in chromatin remodeling components contribute to cancer initiation and progression. In this study, we identified SMARCD1 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily d, member 1) as a novel target gene of miR-7. miR-7 expression reduced SMARCD1 protein expression in lung cancer cell lines. We used luciferase reporters carrying wild type or mutated 3'UTR of SMARCD1 and found that miR-7 blocked SMARCD1 expression by binding to two seed regions in the 3'UTR of SMARCD1 and down-regulated SMARCD1 mRNA expression. Additionally, upon chemotherapy drug treatment, miR-7 down-regulated p53-dependent apoptosis-related gene BAX (BCL2-associated X protein) and p21 expression by interfering with the interaction between SMARCD1 and p53, thereby reducing caspase3 cleavage and the downstream apoptosis cascades. We found that although SMARCD1 sensitized lung cancer cells to chemotherapy drug-induced apoptosis, miR-7 enhanced the drug resistance potential of lung cancer cells against chemotherapy drugs. SMARCD1 was down-regulated in patients with non-small cell lung cancer and lung adenocarcinoma cell lines, and SMARCD1 and miR-7 expression levels were negatively correlated in clinical samples. Our investigation into the involvement of the EGFR-regulated microRNA pathway in the SWI/SNF chromatin remodeling complex suggests that EGFR-mediated miR-7 suppresses the coupling of the chromatin remodeling factor SMARCD1 with p53, resulting in increased chemo-resistance of lung cancer cells.
Insights
Epidermal growth factor receptor (EGFR) upregulates miR-7, which targets SMARCD1. This interaction enhances lung cancer cell resistance to chemotherapy by disrupting p53-mediated apoptosis.
Area of Science:
- Oncology
- Molecular Biology
- Gene Regulation
Background:
- Epidermal growth factor receptor (EGFR) signaling promotes lung cancer growth via miR-7.
- Chromatin remodeling alterations are implicated in cancer development.
- SMARCD1 is a component of the SWI/SNF chromatin remodeling complex.
Purpose of the Study:
- To investigate SMARCD1 as a novel target of miR-7 in lung cancer.
- To elucidate the role of the EGFR-miR-7-SMARCD1 axis in chemoresistance.
Main Methods:
- Luciferase reporter assays to confirm miR-7 binding to SMARCD1 3'UTR.
- Western blotting and qRT-PCR to assess protein and mRNA expression.
- Analysis of SMARCD1 and miR-7 expression in clinical lung cancer samples.
Main Results:
- miR-7 directly targets and down-regulates SMARCD1 expression in lung cancer cells.
- miR-7 interferes with SMARCD1-p53 interaction, reducing p53-dependent apoptosis (BAX, p21).
- SMARCD1 down-regulation and negative correlation with miR-7 observed in non-small cell lung cancer.
Conclusions:
- EGFR-mediated miR-7 suppresses SMARCD1, a chromatin remodeler, leading to increased lung cancer chemoresistance.
- The EGFR-miR-7-SMARCD1 pathway represents a potential therapeutic target for overcoming drug resistance in lung cancer.
Related Concept Videos
MicroRNAs
MicroRNAs
MicroRNAs
Abnormal Proliferation
Negative Regulator Molecules
The Intrinsic Apoptotic Pathway

